Epidemiologic and molecular relationship between vaccine manufacture and autism spectrum disorder prevalence

Issues in Law and Medicine

Volumn 30, Issue 1, 2015, Pages 47-70

  Deisher, Theresa A ^a   Doan, Ngoc V ^a   Koyama, Kumiko ^a   Bwabye, Sarah ^a  

^a Sound Choice Pharmaceutical Institute   (United States)

Author keywords

Autism; DNA uptake; Fetal cell lines; Meiotic recombination hotspot; Vaccine

Indexed keywords

DNA; MEASLES MUMPS RUBELLA VACCINE;

AUTISTIC DISORDER; CELL LINE; CHEMISTRY; DNA FRAGMENTATION; FETUS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; ISOLATION AND PURIFICATION;

AUTISTIC DISORDER; CELL LINE; DNA; DNA FRAGMENTATION; FETUS; HUMANS; MEASLES-MUMPS-RUBELLA VACCINE; MUTAGENESIS, INSERTIONAL;

EID: 84937204700     PISSN: 87568160     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Sebat J, Lakshmi B, Malhotra D, et al. Strong associations of de novo copy number mutations with autism. Science. 2007;316(5823):445.
2. Landa RJ. Diagnosis of autism spectrum disorders in the first 3 years of life. Nature Clinical Practice Neurology. 2008;4(3):138.
3. Deisher T, Koyama K, Bwabye S, Doan N. Impact of environmental factors on the prevalence of autistic disorder after 1979. Journal of Public Health and Epidemiology. 2014:271.
4. McDonald ME, Paul J F. Timing of increased autistic disorder cumulative incidence. Environ Sci Technol. 2010;44(6):2112.
5. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351(9103):637.
6. Dannetun E, Tegnell A, Hermansson G, Törner A, Giesecke J. Timeliness of MMR vaccination-influence on vaccination coverage. Vaccine. 2004;22(31):4228.
7. Trogstad L, Ung G, Hagerup-Jenssen M, Cappelen I, Haugen IL, Feiring B. The norwegian immunisation register-SYSVAK. Euro Surveillance: Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 2012;17(16).
8. Nagaraj A. Does qualitative synthesis of anecdotal evidence with that from scientific research help in understanding public health issues: A review of low MMR uptake. Eur J Public Health. 2006;16(1):85.
9. Yakubov LA, Deeva EA, Zarytova V F, et al. Mechanisms of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Nat'l Acad Sci. 1989:6454-6458.
10. Vlassov V V, Balakireva LA, Yakubov LA. Transport of oligonucleotides across natural and model membranes. Biochim Biophys Acta. 1994;1197(2):95.
11. Orson FM, Thomas D W, McShan WM, Kessler DJ, Hogan ME. Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes. Nucleic Acids Res. 1991;19(12):3435.
12. Zamecnik PC, Goodchild J, Taguchi Y, Sarin PS. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci U S A. 1986;83(12):4143.
13. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2):198.
14. Postel EH, Flint SJ, Kessler DJ, Hogan ME. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci U S A. 1991;88(18):8227.
15. Clarenc J P, Lebleu B, Léonetti J P. Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs. Journal of Biological Chemistry. 1993;268(8):5600.
16. Leonetti J P, Degols G, Clarenc J P, Mechti N, Lebleu B. Cell delivery and mechanisms of action of antisense oligonucleotides. Prog Nucleic Acid Res Mol Biol. 1993;44:143.
17. Zendegui JG, Vasquez KM, Tinsley JH, Kessler DJ, Hogan ME. In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides. Nucleic Acids Res. 1992;20(2):307.
18. Yakubov LA, Rogachev VA, Likhacheva AC, et al. Natural human gene correction by small extracellular genomic DNA fragments. Cell Cycle (Georgetown, Tex.). 2007;6(18):2293.
19. FDA briefing document vaccines and related biological products advisory committee meeting - Cell lines derived from human tumors for vaccine manufacture. September 19, 2012.
20. O'Roak BJ, Vives L, Girirajan S, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012;485(7397):246.
21. Cooper D, Krawczak M, Antonorakis S. The nature and mechanisms of human gene mutation. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. McGraw-Hill; 1995:259.
22. Ozonoff S, Young GS, Carter A, et al. Recurrence risk for autism spectrum disorders: A baby siblings research consortium study. Pediatrics. 2011;128(3):e488.
23. Constantino JN, Zhang Y, Frazier T, Abbacchi AM, Law P. Sibling recurrence and the genetic epidemiology of autism. Am J Psychiatry. 2010;167(11):1349.
24. Sebat J, Lakshmi B, Malhotra D, et al. Strong associations of de novo copy number mutations with autism. Science. 2007;316(5823):445.
25. O'Roak BJ, Vives L, Fu W, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science. 2012;338(6114):1619.
26. Myers S, Bottolo L, Freeman C, McVean G, Donnelly P. A fine-scale map of recombination rates and hotspots across the human genome. Science (New York, N. Y.). 2005;310(5746):321.
27. Girirajan S, Rosenfeld JA, Cooper GM, et al. A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet. 2010;42(3):203.
28. Hicks WM, Kim M, Haber JE. Increased mutagenesis and unique mutation signature associated with mitotic gene conversion. Science (New York, N. Y.). 2010;329(5987):82.
29. Myers S, Freeman C, Auton A, Donnelly P, McVean G. A common sequence motif associated with recombination hot spots and genome instability in humans. Nat Genet. 2008;40(9):1124.
30. Tsai AG, Lieber MR. Mechanisms of chromosomal rearrangement in the human genome. BMC Genomics. 2010;11:1.
31. Baudat F, Buard J, Grey C, et al. PRDM9 is a major determinant of meiotic recombination hotspots in humans and mice. Science (New York, N. Y.). 2010;327(5967):836.
32. Bradley WE, Raelson J V, Dubois DY, et al. Hotspots of large rare deletions in the human genome. PLoS ONE. 2010;5(2):1.
33. Choate KA, Lu Y, Zhou J, et al. Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10. Science (New York, N. Y.). 2010;330(6000):94.
34. Van der Burg M, Pac M, Berkowska MA, et al. Loss of juxtaposition of RAG-induced immunoglobulin DNA ends is implicated in the precursor B-cell differentiation defect in NBS patients. Blood. 2010;115(23):4770.
35. Huang XL, Zou YS, Maher TA, Newton S, Milunsky JM. A de novo balanced translocation breakpoint truncating the autism susceptibility candidate 2(AUTS2) gene in a patient with autism. Am J Med Genetics. Part A. 2010;152A(8):2112.
36. Smith CL, Bolton A, Nguyen G. Genomic and epigenomic instability, fragile sites, schizophrenia and autism. Curr Genomics. 2010;11(6):447.
37. Isaksen J, Diseth TH, Schjølberg S, Skjeldal OH. Observed prevalence of autism spectrum disorders in two norwegian counties. European Journal Of Paediatric Neurology: EJPN: Official Journal of the European Paediatric Neurology Society. 2012;16(6):592.
38. Surén P, Bakken IJ, Aase H, et al. Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in norwegian children. Pediatrics. 2012;130(1):e152.
39. Surén P, Stoltenberg C, Bresnahan M, et al. Early growth patterns in children with autism. Epidemiology. 2013;24(5):660.
40. Nygren G, Cederlund M, Sandberg E, et al. The prevalence of autism spectrum disorders in toddlers: A population study of 2-year-old swedish children... corrected] published erratum appears in J Autism Dev Disord 2012;42(7): 1498]. Journal of Autism & Developmental Disorders. 2012;42(7):1491.
41. Lingam R, Simmons A, Andrews N, Miller E, Stowe J, Taylor B. Prevalence of autism and parentally reported triggers in a north east london population. Arch Dis Child. 2003;88(8):666.
42. Latif AHA, Williams WR. Diagnostic trends in autistic spectrum disorders in the south wales valleys. Autism: The International Journal of Research and Practice. 2007;11(6):479.
43. Population estimates for England and Wales. Office of National Statistics.
44. Feng Z, Hensley L, McKnight KL, et al. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature. 2013;496(7445):367.
45. Namuwulya P, Abernathy E, Bukenya H, et al. Phylogenetic analysis of rubella viruses identified in uganda, 2003-2012. J Med Virol. 2014;86(12):2107.
46. Strizzi L, Hardy KM, Seftor EA, et al. Development and cancer: At the crossroads of nodal and notch signaling. Cancer Res. 2009;69(18):7131.
47. Churbanov A, Voøechovský I, Hicks C. A method of predicting changes in human gene splicing induced by genetic variants in context of cis-acting elements. BMC Bioinformatics. 2010;11:1.
48. Basu SN, Kollu R, Banerjee-Basu S. AutDB: A gene reference resource for autism research. Nucleic Acids Res. 2009;37:D832.
49. The UCSC genome browser. https://genome.ucsc.edu/cgi-bin/hgTables?command=start2013.
50. International hapmap project. http://hapmap. ncbi.nlm.nih.gov/2013.
51. Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: Detection of minority variants and an adventitious virus. J Virol. 2010;84(12):6033.
52. Frank O, Giehl M, Zheng C, Hehlmann R, Leib-Mösch C, Seifarth W. Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorders. J Virol. 2005;79(17):10890.
53. Diem O, Schäffner M, Seifarth W, Leib-Mösch C. Influence of antipsychotic drugs on human endogenous retrovirus (HERV) transcription in brain cells. PLoS ONE. 2012;7(1):1.
54. Balestrieri E, Arpino C, Matteucci C, et al. HERVs expression in autism spectrum disorders. PLoS ONE. 2012;7(11).
55. Tai AK, O'Reilly EJ, Alroy KA, et al. Human endogenous retrovirus-K18 env as a risk factor in multiple sclerosis. Multiple Sclerosis (13524585). 2008;14(9):1175-1180.
56. Freimanis G, Hooley P, Ejtehadi HD, et al. A role for human endogenous retrovirus-K (HML-2) in rheumatoid arthritis: Investigating mechanisms of pathogenesis. Clinical & Experimental Immunology. 2010;160(3):340.
57. Dickerson F, Rubalcaba E, Viscidi R, et al. Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia. Schizophr Res. 2008;104(1-3):121.
58. Chatre L, Ricchetti M. Nuclear mitochondrial DNA activates replication in saccharomyces cerevisiae. PLoS ONE. 2011;6(3):1.
59. Jensen NM, Dalsgaard T, Jakobsen M, et al. An update on targeted gene repair in mammalian cells: Methods and mechanisms. J Biomed Sci. 2011;18(1):10.
60. Colosimo A, Goncz KK, Novelli G, Dallapiccola B, Gruenert DC. Targeted correction of a defective selectable marker gene in human epithelial cells by small DNA fragments. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2001;3(2):178.
61. Colosimo A, Guida V, Antonucci I, Bonfini, Stuppia L, Dallapiccola B. Sequence-specific modification of a beta-thalassemia locus by small DNA fragments in human erythroid progenitor cells. Haematologica. 2007;92(1):129.
62. McNeer NA. Schleifman EB, Cuthbert A. et al. Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo. Gene Ther. 2013;20(6):658-669.
63. Filaci G. Gerloni M, Rizzi M, et al. Spontaneous transgenesis of human B lymphocytes. Gene Ther. 2004;11(1):42.
64. Lehmann MJ, Sczakiel G. Spontaneous uptake of biologically active recombinant DNA by mammalian cells via a selected DNA segment. Gene Ther. 2005;12(5):446.
65. Rogachev VA, Likhacheva A, Vratskikh O, et al. Qualitative and quantitative characteristics of the extracellular DNA delivered to the nucleus of a living cell. Cancer Cell International. 2006;6:23.
66. Yakubov LA, Petrova NA, Popova NA, Semenov D V, Nikolin V P, Os'kina IN. The role of extracellular DNA in the stability and variability of cell genomes. Doklady. Biochemistry And Biophysics. 2002;382:31.
67. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143.
68. Michaelson JJ, Shi Y, Gujral M, et al. Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell. 2012;151(7):1431.
69. Orenstein W, Reef SE. Rubella virus. In: Kaslow RA, Stanberry LR, Le Duc J W, eds. Viral Infections of Humans: Epidemiology and Control. Fifth ed. Springer; 2014:733-744
70. Shiraki K, Hayakawa Y, Mori H, et al. Development of immunogenic recombinant oka varicella vaccine expressing hepatitis B virus surface antigen J Gen Virol. 1991;72(Pt 6):1393.
71. Diaz-Mitoma F, Le T, Anderson DE. Compositions and methods for treating hepatitis a. http://www.google.com/patents/WO2010033812A1?cl=en.